November 1st 2021
The FDA has given its approval to Byooviz (ranibizumab-nuna, SB11, Samsung Bioepis Co Inc and Biogen Inc), a biosimilar referencing Lucentis (ranibizumab, Genentech).
Application of Recent Data in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Managed Care Insights and Strategies
View More
(CME Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(COPE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(CME/CNE Credit) Community Practice Connections™: Restoring the Surface Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(CME/CNE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(CME Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
(COPE Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
(COPE Credit) Community Practice Connections™: Restoring the Surface – Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
18th Annual Controversies in Modern Eye Care
May 4, 2024
Register Now!
Headed to ARVO? You’re invited to dinner COPE CE/CME. Or join virtually!
May 6 & 7, 2024
Register Now!
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
2nd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
May 18-19, 2024
Register Now!
(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(CME Credit) Virtual Case Studies™ in Cataract Surgery: Selecting Surgical Techniques and Preventing Intra-Operative Complications
View More
(COPE Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
Neurotrophic Keratitis Management: How Early Intervention Can Make a Difference
View More
(CME Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
17th Annual Controversies in Modern Eye Care
View More
Thyroid Eye Disease: The Masquerading Eye Disorder—A Guide to Collaborative Care and Accurate Diagnosis
View More
(COPE Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
(CME Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(COPE Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(COPE Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(CME Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(CME Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
What’s New in MGD Beyond Heating and Squeezing?
View More
The Ins and Outs of Lubricating Eye Drops
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Expert Perspectives in Diabetic Macular Edema – Considering Pathogenesis & Inflammation in Treatment Selection
View More
Increased tear production: Restasis approval a milestone for dry eye
February 1st 2003The FDA approval of cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan) Dec. 26 marked a landmark for ophthalmology. The eye drop therapy for moderate to severe keratoconjunctivitis sicca is unique in that it treats the inflammatory process that causes the condition, and not just its symptoms.
Read More
Wavefront-guided LASIK: Customized approach improves vision quality
February 1st 2003Orlando-CustomCornea wavefront-guided LASIK using the LADARWave aberrometer and the LADARVision4000 excimer laser (Alcon) last October became the first wavefront-guided LASIK system to receive FDA approval for the treatment of myopia. The agency's decision was based on clinical trial data proving that the customized approach delivers superior optical quality compared with conventional LASIK.
Read More
International partners: InSite Vision, SIFI take OcuGene test to Italy
February 1st 2003Alameda, CA-InSite Vision Inc. and SIFI (Societa Industria Farmaceutica Italiana), a leading Italian pharmaceutical company, will exclusively manufacture, distribute, and promote the OcuGene genetic glaucoma test in Italy.
Read More
Diffractive multifocal lens reduces halo complaints
December 15th 2002Nice, France-The diffractive/refractive, fold-able, multifocal AcrySof IOL (study model MA60D3, Alcon, Fort Worth, TX) achieves similar mean distance vision and better near vision compared with the Array multifocal SA40N IOL (AMO, Santa Ana, CA), an FDA-approved IOL. Importantly, patients reported significantly fewer complaints of halos compared with the SA40N IOL, according to Philippe Dublineau, MD.
Read More
Orlando-Cataract and refractive surgeons have worked hard over the last decade, perfecting their surgical techniques. Small-incision cataract surgery has revolutionized the ophthalmic profession as have developments in laser refractive procedures. But surgical technique is only part of the equation for producing outstanding surgical outcomes. Prevention of post-surgical infection is another concern.
Read More
Technology making waves in refractive surgery
December 15th 2002Like other areas of ophthalmology, refractive surgery enjoyed a number of refinements and advancements over the past year, including the FDA approval of both wavefront technology and conductive keratoplasty for hyperopia, and advances in refractive IOLs, among others. However, wavefront technology took center stage as the development cited as having the most potential benefit for patients undergoing refractive procedures. Several refractive surgeons weigh in on advances in their subspecialty in 2002.
Read More
Phakic IOLs offer promise from a U.S. surgeon's perspective
December 15th 2002In a recent Market Scope report onphakic IOLs, editor David Harmon observes: "Phakic IOLs have become a standard part of the European ophthalmologist's tool kit. CE Mark regulatory approval has been granted to four manufacturers of the devices . . . Europe has become the center of worldwide phakic IOL clinical experience . . . European surgeons implanted an estimated 15,350 phakic IOLs last year."
Read More
Anecortave acetate administration shows promise for subfoveal, exudative AMD
December 1st 2002San Francisco-The angiostatic steroid anecortave acetate continues to show promise as a safe and effective treatment for subfoveal, exudative age-related macular degeneration (AMD), according to results from an interim analysis of an ongoing phase II trial.
Read More
Once-daily glaucoma therapy better tolerated than b.i.d.
November 15th 2002Houston-In patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH), once-daily treatment with fixed-combination latanoprost/timolol (Xalacom, Pharmacia, Peapack, NJ) is well tolerated and lowers IOP more effectively than twice-daily dorzolamide/timolol (Cosopt, Merck), according to a recent multicenter U.S. study.
Read More
IOP-reducing effects of latanoprost, unoprostone weighed
November 15th 2002Baltimore-Latanoprost 0.005% (Xalatan, Pharmacia) taken once daily is more effective in lowering IOP than unoprostone 0.15% (Rescula, Novartis) taken twice daily, according to a recent multicenter study, reported Henry D. Jampel, MD, MHS.
Read More
Inhaled cocaine use linked to nonischemic vascular event
November 1st 2002A 42-year-old Hispanic male presented complaining of decreased vision in his left eye. He noted that his vision in that eye had decreased suddenly three weeks earlier. The patient had low hyperopia. His medical, surgical, and family histories were unremarkable. He was using no medications and had no known drug allergies. Although he initially reported no significant social history, after more extensive questioning he admitted to the occasional inhalational use of cocaine. His most recent use was on the day prior to the onset of his visual disturbance.
Read More
Posterior chamber PRL corrects moderate to high hyperopia
November 1st 2002Rockville Centre, NY-Implantation of a posterior chamber phakic refractive lens (PRL) (Medennium phakic refractive lens, CIBA Vision, Duluth, GA) demonstrated positive visual outcomes in the treatment of high hyperopia, according to Alexander Hatsis, MD, who presented the results of the FDA phase II trial.
Read More
Santen hopes to build its presence through collaboration
November 1st 2002Napa, CA-When Santen Inc. entered the U.S. marketplace, the company's initial corporate campaign featured a bright-eyed, smiling little girl named Molly. The little girl was the focal point of the campaign that was entitled, "Protecting the Joy of Sight."
Read More
Anterior chamber lens holds promise for high hyperopia
October 15th 2002Stanford, CA-The Artisan hyperopia lens (Ophtec BV, Groningen, The Netherlands) appears to provide good visual results for extreme hyperopia ranging from 3 to 12 D, according to phase III results reported by Edward E. Manche, MD, assistant professor of ophthalmology and director of cornea and refractive surgery, Stanford University School of Medicine, Stanford, CA.
Read More
Head-to-head trial: Phase III study tests options for wet AMD
October 15th 2002Fort Worth, TX-Alcon Research Ltd. is enrolling about 500 patients in a phase III study to compare the effects of anecortave acetate versus verteporfin (Visudyne, Novartis) photodynamic therapy for the treatment of wet age-related macular degeneration.
Read More
Commitment to R&D strengthens Allergan product pipeline
October 1st 2002Irvine, CA-When Allergan announced in January that it planned to spin off its optical medical device business into a separate company called Advanced Medical Optics (AMO), David E.I. Pyott, chairman, president, and CEO of Allergan, said the company would evolve into a specialty pharmaceutical company.
Read More